Journal article
Schistosoma mansoni infections are associated with faecal calprotectin markers of gut inflammation after accounting for HIV, hepatitis B, and malaria
- Abstract:
-
Background
The role of gut inflammation for intestinal schistosomiasis remains poorly understood in chronically infected and repeatedly treated populations.
Methods
We conducted a cross-sectional study nested in the SchistoTrack cohort within Pakwach district, Uganda. In 2024, 640 participants aged 6-85 years were examined for Schistosoma mansoni by KatoKatz. fCal concentration was measured by ELISA. fCal was analysed as binary outcomes (detectable, ≥100 µg/g, >250 µg/g) and natural log-transformed continuous values. Co-endemic infections (malaria, HIV, hepatitis B (HBV)) and diverse sociodemographic covariates were investigated in logistic regressions with covariate selection. Correlations of symptoms, medications, and circulating white blood cells (WBC) with infections and fCal were reported.
Results
74.4% of participants had detectable fCal, 22.3% had fCal ≥100 µg/g, and 7% had fCal >250 µg/g. S. mansoni prevalence was 49.1% (median 144 eggs per gram, IQR 36-369). Infection intensity was positively associated with all fCal outcomes (detectable: OR 1.20, ≥100 µg/g: OR 1.11, >250 µg/g: OR 1.26; continuous: β = 0.06) while status was positively related to all but the continuous fCal outcome. HIV was associated with fCal ≥100 µg/g (OR 2.52), while malaria and HBV were uninformative. Spearman analyses revealed significant and weak positive correlations between fCal, WBCs (neutrophils, monocytes and lymphocytes), faecal occult blood, medications (praziquantel and antiinflammatories) and gastrointestinal symptoms (blood in stool).
Conclusions
S. mansoni infections are characterised by persistent, clinically concerning levels of gut inflammation in chronically infected populations with repeated praziquantel treatment. Integration of fCal thresholds into clinical guidelines may improve management of schistosomiasis-related morbidity.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 988.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/infdis/jiag094
Authors
- Publisher:
- Oxford University Press
- Journal:
- Journal of Infectious Diseases More from this journal
- Publication date:
- 2026-04-29
- Acceptance date:
- 2026-02-09
- DOI:
- EISSN:
-
1537-6613
- ISSN:
-
0022-1899
- Language:
-
English
- Keywords:
- Pubs id:
-
2384071
- Local pid:
-
pubs:2384071
- Deposit date:
-
2026-03-09
- ARK identifier:
Terms of use
- Copyright holder:
- Wilburn et al
- Copyright date:
- 2026
- Rights statement:
- © The Author(s) 2026. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
- Notes:
- This article has been accepted for publication in Journal of Infectious Diseases.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record